Introduction
Methods
Gene | Primer | Trial | Primer sequence (5′-3′) | Position | Size | Success rate | Ref |
---|---|---|---|---|---|---|---|
E6 | E6-a-F | 1 | AGAAACACACCACAATACTATGGCG | 86 | 661 | 86/170 | [21] |
E6-a-R | GTCGGGCTGGTAAATGTTGAT | 746 | |||||
E6-b-F | 2 | GGGACCGAAAACGGTGTAT | 55 | 611 | 11/79 | [22] | |
E6-b-R | GAAGGTCAACCGGAATTTCA | 665 | |||||
E6-c-F | 3 | GGGACCGAAAACGGTGTAT | 55 | 557 | 0/68 | [22] | |
E6-c-R | ATGTTGCCTTAGGCTCCATGC | 611 | |||||
E7 | E7-a-F | 1 | CGACAGGAACGACTCCAACGA | 540 | 431 | 165/170 | [21] |
E7-a-R | ATAAAACCAGCCGTTACAACCCGTG | 970 | |||||
L1 | L1–1-a-F | 1 | GTAACGGTCCCTTTAACCTCCTC | 5402 | 650 | 153/170 | [21] |
L1–1-a-R | CATTGTCCCTAACGTCCTCAG | 6051 | |||||
L1–2-a-F | AAGTTCCCATGCCGCCACGTCTAAT | 6002 | 505 | 162/170 | |||
L1–2-a-R | AGAGCCACTTGGAGAGGGAGAATAC | 6506 | |||||
L1–3-a-F | GCTCTATTGTTACCTCTGACTCC | 6502 | 636 | 32/170 | |||
L1–3-a-R | ATTACTTCCTGGCACGTACACGCAC | 7137 | |||||
L1–3-b-F | 2 | AGTTATGTATTTTGGGCTGTG | 6077 | 756 | 0/128 | [10] | |
L1–3-b-R | ACACCAAAGTTCCAATCCTCTAA | 6832 | |||||
L1–3-b’-F | AGTATAGCAGACATGTTGAGGAA | 6699 | 551 | 0/128 | |||
L1–3-b’-R | CATACAACATACAACAACAACCAT | 7249 | |||||
L1–3-c-F | 3 | TCCCTCTCCAAGTGGCTCTA | 6488 | 601 | 44/128 | [22] | |
L1–3-c-R | AGTGGCAGATGGAGCAGAAC | 7088 |
Results
HPV18 variants
Association between HPV18 variants and cervical lesion severity
AA(n = 89) | E(n = 8) | P value | ||
---|---|---|---|---|
Age, years | 46 (40–54) | 58 (47–63) | 0.344* | |
Cervical lesion, n | Grouping | |||
Normal | ① | 22 (24.7%) | 3 (37.5%) | 0.298† |
ASCUS | ② | 5 (5.6%) | 2 (25.0%) | |
LSIL/CIN1 | ③ | 34 (38.2%) | 1 (12.5%) | |
HSIL/CIN2&3 | ④ | 17 (19.1%) | 1 (12.5%) | |
Cancer | ⑤ | 11 (12.4%) | 1 (12.5%) | |
Pathology and treatment, n | ||||
Cancer | ⑤ | 11 (12.4%) | 1 (12.5%) | 1.000‡ |
Non-cancer | ① + ② + ③ + ④ | 78 (87.6%) | 7 (87.5%) | |
Surgery | ④ + ⑤ | 28 (31.5%) | 2 (25.0%) | 1.000‡ |
Observation | ① + ② + ③ | 61 (68.5%) | 6 (75.0%) | |
Definite dysplasia | ③ + ④ + ⑤ | 62 (69.7%) | 3 (37.5%) | 0.110‡ |
Normal and ASCUS | ① + ② | 27 (30.3%) | 5 (62.5%) | |
Evidence of co-infection, n | ||||
With other risk type(s) | 21 (23.6%) | 2 (25.0%) | 1.000‡ | |
With other high-risk type(s) | 16 (18.0%) | 1 (12.5%) | 1.000‡ | |
§Serial follow-up testing (n = 54) | ||||
Progression (n) | n = 50 | n = 4 | ||
Progression | 21 (42.0%) | 1 (25.0%) | 0.773‡ | |
No progression | 29 (58.0%) | 3 (75.0%) |